Poland
· Delayed Price · Currency is PLN Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of PLN 102.60 million. The enterprise value is 97.68 million.
| Market Cap | 102.60M |
| Enterprise Value | 97.68M |
Important Dates
The last earnings date was Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomtec has 13.32 million shares outstanding. The number of shares has increased by 27.53% in one year.
| Shares Outstanding | 13.32M |
| Shares Change (YoY) | +27.53% |
| Shares Change (QoQ) | -10.17% |
| Owned by Insiders (%) | 13.82% |
| Owned by Institutions (%) | 5.56% |
| Float | 9.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 16.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.22 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 33.04.
| Current Ratio | 1.12 |
| Quick Ratio | 1.04 |
| Debt / Equity | 33.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -75.67 |
Financial Efficiency
Return on equity (ROE) is -226.95% and return on invested capital (ROIC) is -93.20%.
| Return on Equity (ROE) | -226.95% |
| Return on Assets (ROA) | -41.61% |
| Return on Capital (ROIC) | -93.20% |
| Revenue Per Employee | -5,235 |
| Profits Per Employee | -564,235 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.96% in the last 52 weeks. The beta is 0.40, so Genomtec's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -25.96% |
| 50-Day Moving Average | 8.86 |
| 200-Day Moving Average | 10.54 |
| Relative Strength Index (RSI) | 43.91 |
| Average Volume (20 Days) | 44,004 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of PLN -89,000 and -9.59 million in losses. Loss per share was -0.75.
| Revenue | -89,000 |
| Gross Profit | -1.27M |
| Operating Income | -9.31M |
| Pretax Income | -9.59M |
| Net Income | -9.59M |
| EBITDA | -7.68M |
| EBIT | -9.31M |
| Loss Per Share | -0.75 |
Balance Sheet
The company has 6.79 million in cash and 1.87 million in debt, giving a net cash position of 4.92 million or 0.37 per share.
| Cash & Cash Equivalents | 6.79M |
| Total Debt | 1.87M |
| Net Cash | 4.92M |
| Net Cash Per Share | 0.37 |
| Equity (Book Value) | 5.64M |
| Book Value Per Share | 0.46 |
| Working Capital | 902,000 |
Cash Flow
In the last 12 months, operating cash flow was -3.58 million and capital expenditures -2.45 million, giving a free cash flow of -6.02 million.
| Operating Cash Flow | -3.58M |
| Capital Expenditures | -2.45M |
| Free Cash Flow | -6.02M |
| FCF Per Share | -0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | 10,457.30% |
| Pretax Margin | 10,777.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 6,768.54% |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.53% |
| Shareholder Yield | -27.53% |
| Earnings Yield | -9.79% |
| FCF Yield | -5.87% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 1.03. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.03 |
| Piotroski F-Score | n/a |